Kolltan Pharmaceuticals, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Kolltan Pharmaceuticals, Inc. - overview
Established
2007
Location
New Haven, CT, US
Primary Industry
Pharmaceuticals
About
Founded in 2007, Kolltan Pharmaceuticals, Inc. develops monoclonal antibody oncology therapeutics for the treatment of cancer and other diseases.
Current Investors
HBM Partners, Auven Therapeutics, Purdue Pharma
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Epidemiology, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Verticals
HealthTech
Company Stage
Acquired
Total Amount Raised
Subscriber access only
Kolltan Pharmaceuticals, Inc. - financials
| Fiscal Year Ended | Dec 31, 2013 |
|---|---|
| Revenue (USD) | - |
| % Revenue Growth (YoY) | - |
| EBITDA (USD) | - |
| Operating Income (USD) | - |
| Operating Margin | - |
| % EBITDA Margin | - |
| NET Income (USD) | - |
| % Net Margin | - |
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.